Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher [Seeking Alpha]
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
The PSVT market is crowded with effective, cheap oral generics and ablation, making MIST's premium pricing and differentiation difficult to justify. RAPID trial data failed to show significant advantages for CARDAMYST in rapid (10-minute) conversion or ED avoidance, undermining its value proposition to payers and prescribers. I maintain a neutral Hold rating for MIST stock, as CARDAMYST's market opportunity appears niche and MIST must prove commercial traction amid substantial risks. OJO Images/OJO Images via Getty Images Introduction Milestone Pharmaceuticals Inc. ( MIST ) news reached my desk last week with the FDA approval of its nasal spray, CARDAMYST , which is described as a “calcium channel blocker indicated for the conversion of This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article m
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- Milestone Pharmaceuticals (NASDAQ:MIST) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Cowen Inc from a "hold" rating to a "buy" rating.MarketBeat
- Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock.MarketBeat
MIST
Earnings
- 11/12/25 - Beat
MIST
Sec Filings
- 12/15/25 - Form 8-K
- 12/11/25 - Form 4
- 11/14/25 - Form SCHEDULE
- MIST's page on the SEC website